NCT02436096 - A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia | Biotech Hunter

Enrollment

519

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

FibromyalgiaMyofascial Pain SyndromesMuscular DiseasesMusculoskeletal DiseasesNervous System DiseasesNeuromuscular DiseasesRheumatic Diseases

Interventions

DRUG

TNX-102 SL Tablet, 2.8mg

Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.

DRUG

Placebo SL Tablet

Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.

Trial Locations (35)

14221

Williamsville

18104

Allentown

22911

Charlottesville

23507

Norfolk

29464

Mt. Pleasant

29650

Greer

30080

Smyrna

31904

Columbus

32720

DeLand

32806

Orlando

33409

West Palm Beach

33511

Brandon

33613

Tampa

33614

Tampa

33805

Lakeland

34471

Ocala

35216

Birmingham

39202

Jackson

43212

Columbus

44130

Middleburg Heights

45206

Cincinnati

47714

Evansville

48104

Ann Arbor

53142

Kenosha

75231

Dallas

84102

Salt Lake City

85032

Phoenix

92103

San Diego

95825

Sacramento

97210

Portland

97504

Medford

98007

Bellevue

98104

Seattle

02747

North Dartmouth

02888

Warwick

All Listed Sponsors

lead

Tonix Pharmaceuticals, Inc.

INDUSTRY